Patents by Inventor Yiannis Ioannou
Yiannis Ioannou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190201377Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a pharmaceutically effective amount of bryostatin 1.Type: ApplicationFiled: January 15, 2019Publication date: July 4, 2019Inventors: Yiannis A. IOANNOU, Lawrence ALTSTIEL, David R. CROCKFORD, Sathapana KONGSAMUT
-
Patent number: 10239830Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.Type: GrantFiled: February 11, 2016Date of Patent: March 26, 2019Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, The United States of America, as represented by the Secretary, Depart. of Health and Human ServicesInventors: Samarjit Patnaik, Mercedes Taylor, Raul Rolando Calvo, Juan Jose Marugan, Noel Southall, Wei Zheng, Marc Ferrer-Alegre, Seameen Dehdasthi, Patricia Dranchak, Fannie Chen, Yiannis Ioannou
-
Publication number: 20180044286Abstract: Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides.Type: ApplicationFiled: February 11, 2016Publication date: February 15, 2018Applicants: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, and Human ServicesInventors: Samarjit PATNAIK, Mercedes TAYLOR, Raul Rolando CALVO, Juan Jose MARUGAN, Noel SOUTHALL, Wei ZHENG, Marc FERRER-ALEGRE, Seameen DEHDASTHI, Patricia DRANCHAK, Fannie CHEN, Yiannis IOANNOU
-
Patent number: 9724328Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.Type: GrantFiled: April 14, 2015Date of Patent: August 8, 2017Assignees: Icahn School of Medicine at Mount Sinai, Neurotrope BioscienceInventors: Yiannis A. Ioannou, Lawrence Altstiel, David R. Crockford, Sathapana Kongsamut
-
Publication number: 20170172978Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids. Accordingly, the present disclosure provides methods for treating human subjects suffering from lipid storage disorders, such as Niemann-Pick disease, by administering PKC activators. The present disclosure provides, according to certain embodiments, methods comprising administering to a subject with Niemann-Pick Type C disease a pharmaceutically effective amount of bryostatin 1.Type: ApplicationFiled: April 14, 2015Publication date: June 22, 2017Inventors: Yiannis A. IOANNOU, Lawrence ALTSTIEL, David R. CROCKFORD, Sathapana KONGSAMUT
-
Publication number: 20150297559Abstract: Treating subjects having a lipid storage disorder with a composition comprising a PKC activator, such as bryostatins, bryologs, and polyunsaturated fatty acids.Type: ApplicationFiled: April 14, 2015Publication date: October 22, 2015Inventors: Yiannis A. IOANNOU, Lawrence Altstiel, David R. CROCKFORD, Sathapana KONGSAMUT
-
Publication number: 20100119525Abstract: The present invention relates to a method for prolonging longevity using and NPC1L1 antagonist. The present invention also provides a method for reducing weight in an individual who consumes a high-fat diet using an NPC1L1 antagonist.Type: ApplicationFiled: August 1, 2006Publication date: May 13, 2010Applicant: MOUNT SINAI SCHOOOL OF MEDICINE OF NEW YORK UNIVERSITYInventor: Yiannis Ioannou
-
Publication number: 20090035784Abstract: The present invention provides a novel gene, designated herein as “NPC1L1”, that is associated with lipid or glucose metabolism. The invention further provides the use of the NPC1L1 gene and its corresponding protein to diagnose a lipid condition in a cell or tissue and to screen for novel therapeutic compounds useful for treating lipid disorders and other NPC1L1-associated or mediated diseases or disorders. The invention further provides specific inhibitors of NPC1L1.Type: ApplicationFiled: August 1, 2005Publication date: February 5, 2009Applicant: Mount Sinai School of Medicine of New York UniversityInventors: Yiannis Ioannou, Joanna P. Davies
-
Patent number: 6455037Abstract: The present invention relates to methods and compositions for the reduction of xenotransplantation rejection. Specifically, the present invention relates, first, to transgenic cells, tissues, organs and animals containing transgenic nucleic acid molecules that direct the expression of gene products, including, but not limited to enzymes, capable of modifying, either directly or indirectly, cell surface carbohydrate epitopes such that the carbohydrate epitopes are no longer recognized by natural human antibodies or by the human cell-mediated immune response, thereby reducing the human immune system response elicited by the presence of such carbohydrate epitopes. In a preferred embodiment, the transgenic cells, tissues, organs and animals express nucleic acid molecules encoding functional recombinant &agr;-Galactosidase A (&agr;GalA) enzyme which modifies the carbohydrate epitope Gal&agr;(1,3)Gal.Type: GrantFiled: November 1, 1996Date of Patent: September 24, 2002Assignees: Mount Sinai School of Medicine of the City University of New York, The Austin Research InstituteInventors: Yiannis Ioannou, Robert J. Desnick, Mauro S. Sandrin, Ian F. C. McKenzie
-
Patent number: 5580757Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used, but is not limited to, in the treatment in Fabry Disease; for the hydrolysis of .alpha.Type: GrantFiled: June 17, 1994Date of Patent: December 3, 1996Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou
-
Patent number: 5491075Abstract: The present invention involves the production of human .alpha.-GalNAc by cloning and expressing the .alpha.-GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced.The .alpha.-GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in various glycoconjugates.Type: GrantFiled: June 17, 1994Date of Patent: February 13, 1996Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou, Anne M. Wang
-
Patent number: 5401650Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used, but is not limited to, in the treatment in Fabry Disease; for the hydrolysis of .alpha.Type: GrantFiled: November 30, 1992Date of Patent: March 28, 1995Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou
-
Patent number: 5382524Abstract: The present invention involves the production of human .alpha.-GalNAc by cloning and expressing the .alpha.-GalNAc coding sequence in eukaryotic host cell expressions systems. The eukaryotic expression systems, and in particular the mammalian host cell expression systems described herein provide for the appropriate co-translational and post-translation modifications required or proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced.The .alpha.-GalNAc produced in accordance with the invention may be used in the treatment of Schindler disease or for the hydrolysis of .alpha.-N-acetylgalactosaminyl moieties in various glycoconjugates.Type: GrantFiled: October 24, 1990Date of Patent: January 17, 1995Assignee: The Mount Sinai School of Medicine of the City University of New YorkInventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou, Anne M. Wang
-
Patent number: 5356804Abstract: The present invention involves the production of large quantities of human .alpha.-Gal A by cloning and expressing the .alpha.-Gal A coding sequence in eukaryotic host cell expression systems. The eukaryotic expression systems, and in particular the mammalian host cell expression system described herein provide for the appropriate cotranslational and posttranslational modifications required for proper processing, e.g., glycosylation, phosphorylation, etc. and sorting of the expression product so that an glycosylation, phosphorylation, etc. and sorting of the expression product so that an active enzyme is produced. In addition, the expression of fusion proteins which simplify purification is described.Using the methods described herein, the recombinant .alpha.-Gal A is secreted by the engineered host cells so that it is recovered from the culture medium in good yield. The .alpha.-Gal A produced in accordance with the invention may be used in the treatment in Fabry Disease; for the hydrolysis of .alpha.Type: GrantFiled: October 24, 1990Date of Patent: October 18, 1994Assignee: Mount Sinai School of Medicine of the City of New YorkInventors: Robert J. Desnick, David F. Bishop, Yiannis A. Ioannou